Abstract
Ipilimumab, a fully human monoclonal antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), is the new hope in the treatment of patients with advanced melanoma. Anti-CTLA-4 antibodies enhance T cell responses in vitro and in vivo and activate proliferation of tumour-specific T cells. The blockade of CTLA-4 by ipilimumab leads to immune-mediated tumor regression. Ipilimumab has been studied in metastatic melanoma in a number of clinical trials. Recently, a phase III, multi-center, randomized, double-blind trial showed a significant improvement in overall survival in patients with advanced melanomas treated with ipilimumab. Thus, ipilimumab was the first drug to demonstrate effect on overall survival in patients with metastatic melanoma. However, patients treated with ipilimumab develop various immune-related adverse events (irAEs), which are associated with objective and durable clinical responses. Use of new immune-related response criteria is recommended in patients on ipilimumab therapy to avoid premature treatment discontinuation. Further research is necessary to elucidate role of ipilimumab in adjuvant setting as well as in synergy with other novel modalities for the treatment of metastatic melanoma.
Keywords: Melanoma, ipilimumab, CDTLA-4, antibody, immunotherapy, monoclonal antibody, metastatic melanoma, tumour-associated antigens, monoclonal antibodies, glycoprotein, malignancies, subcutaneous vaccinations, melanomaassociated antigen, ipilimumab monotherapy, cytotoxic agents
Current Topics in Medicinal Chemistry
Title: Ipilimumab Targeting CD28-CTLA-4 Axis: New Hope in the Treatment of Melanoma
Volume: 12 Issue: 1
Author(s): Marko Lens, Alessandro Testori and Pier Francesco Ferucci
Affiliation:
Keywords: Melanoma, ipilimumab, CDTLA-4, antibody, immunotherapy, monoclonal antibody, metastatic melanoma, tumour-associated antigens, monoclonal antibodies, glycoprotein, malignancies, subcutaneous vaccinations, melanomaassociated antigen, ipilimumab monotherapy, cytotoxic agents
Abstract: Ipilimumab, a fully human monoclonal antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), is the new hope in the treatment of patients with advanced melanoma. Anti-CTLA-4 antibodies enhance T cell responses in vitro and in vivo and activate proliferation of tumour-specific T cells. The blockade of CTLA-4 by ipilimumab leads to immune-mediated tumor regression. Ipilimumab has been studied in metastatic melanoma in a number of clinical trials. Recently, a phase III, multi-center, randomized, double-blind trial showed a significant improvement in overall survival in patients with advanced melanomas treated with ipilimumab. Thus, ipilimumab was the first drug to demonstrate effect on overall survival in patients with metastatic melanoma. However, patients treated with ipilimumab develop various immune-related adverse events (irAEs), which are associated with objective and durable clinical responses. Use of new immune-related response criteria is recommended in patients on ipilimumab therapy to avoid premature treatment discontinuation. Further research is necessary to elucidate role of ipilimumab in adjuvant setting as well as in synergy with other novel modalities for the treatment of metastatic melanoma.
Export Options
About this article
Cite this article as:
Lens Marko, Testori Alessandro and Francesco Ferucci Pier, Ipilimumab Targeting CD28-CTLA-4 Axis: New Hope in the Treatment of Melanoma, Current Topics in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/156802612798919231
DOI https://dx.doi.org/10.2174/156802612798919231 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Tumor-Induced Alterations in Lipid Metabolism
Current Medicinal Chemistry Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design Role of microRNA Deregulation in Breast Cancer Cell Chemoresistance and Stemness
Current Medicinal Chemistry Cancer Control by Phytochemicals
Current Pharmaceutical Design Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Manipulating Intracellular Ca2+ Signals to Stimulate Therapeutic Angiogenesis in Cardiovascular Disorders
Current Pharmaceutical Biotechnology Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design Coronary CT Angiography in the Diagnosis of Coronary Artery Disease
Current Medical Imaging Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism Modified Nucleosides That Can Be Incorporated into DNA Enzymatically or in Live Cells
Current Organic Chemistry The Functional Role of Oncogenic LncRNA BCAR4 for Cancer Outcome
Current Pharmaceutical Design Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design Natural Products from Deep-Sea-Derived Fungi ̶ A New Source of Novel Bioactive Compounds?
Current Medicinal Chemistry Differentiated Thyroid Carcinoma and Intestinal Polyposis Syndromes
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Patents on Biomarkers in Oral Cancers
Recent Patents on Biomarkers Role of Natural Killer Cell Activity in the Pathogenesis of Endometriosis
Current Medicinal Chemistry [1, 2, 4]-Oxadiazoles: Synthesis and Biological Applications
Mini-Reviews in Medicinal Chemistry